Vaccine Discovery and Preclinical Development
Vaccine development requires alignment between antigen design, delivery platform, formulation and the immune response needed for protection or therapeutic activity. Decisions made at the discovery stage can influence antigen stability, epitope presentation, manufacturability and performance in later studies. Creative Biolabs provides research services supporting vaccine programs from target and antigen selection through formulation and preclinical evaluation.
Programmes can be designed for infectious diseases, therapeutic cancer vaccines and other research applications. Individual services are also available for teams with an established antigen or platform.
Target and antigen discovery
A vaccine programme begins with a clear biological rationale for the selected antigen. Creative Biolabs supports target identification, antigen selection, epitope analysis and immunogenicity assessment.
Sequence conservation, antigen accessibility, structural features and potential cross-reactivity can be considered when prioritising candidates. For multi-antigen or multivalent programmes, the design strategy can also examine whether the selected components provide complementary immune coverage without interfering with antigen expression or presentation.
Selected antigens may be produced and characterised before entering formulation or in vivo studies. Relevant testing can include identity, purity, structural integrity, binding activity and stability.
Vaccine platform design
Creative Biolabs supports a range of vaccine technologies, including recombinant protein, peptide, nucleic acid, viral vector and virus-like particle platforms. Platform selection is guided by the antigen, intended immune response, delivery requirements and practical development considerations.
For recombinant protein and peptide vaccines, services may include antigen engineering, expression-system selection and construct optimisation. Nucleic acid vaccine projects can involve DNA or mRNA design, sequence optimisation and delivery development. Viral vector projects may require vector selection, expression cassette design and confirmation of antigen expression. Virus-like particle programmes can include antigen display strategy and particle characterisation.
Platform comparisons can be incorporated when the most appropriate approach has not yet been established.
Adjuvant and formulation development
The formulation must preserve antigen quality while promoting an appropriate immune response. Creative Biolabs provides adjuvant screening and formulation studies for protein, peptide and other vaccine formats.
Formulation variables may include adjuvant type, antigen-to-adjuvant ratio, buffer composition, pH, excipients and preparation conditions. Candidate formulations can be assessed for physical stability, aggregation, particle characteristics, antigen integrity and compatibility with the proposed administration route.
Adjuvant selection is based on the required immune profile rather than the magnitude of the response alone. Depending on the vaccine concept, studies may compare humoral responses, T-cell responses or a combination of both.
Immunogenicity and functional testing
Preclinical immunogenicity studies can measure antigen-specific antibody titres, antibody isotypes, binding activity and response durability. Where relevant, functional assays may assess neutralisation, inhibition of pathogen entry or other antigen-specific biological effects.
Cellular immunity can be evaluated through T-cell activation, cytokine production, proliferation and antigen-specific response assays. These data help determine whether a candidate induces the type of immunity intended by the vaccine design.
Preclinical evaluation
Selected candidates may progress to disease-relevant models for evaluation of dose, schedule, route of administration, immunogenicity and tolerability. Efficacy endpoints are selected according to the vaccine type and model and may include pathogen burden, disease-associated readouts or tumour growth control.
By reviewing antigen quality, formulation attributes and biological responses together, Creative Biolabs helps research teams compare vaccine candidates and make informed decisions before further development.
Contact Creative Biolabs to discuss a vaccine discovery or preclinical development programme.
